EP4041764A1 - USE OF AN ANTI-CCR7 ANTIBODY IN COMBINATION THERAPIES WITH A BTK INHIBITOR AND/OR BCL2- INHIBITOR FOR TREATING HEMATOLOGICAL MALIGNANCIES